Feedback / Questions
Ampligen (rintatolimod) - AIM ImmunoTech
https://www.globenewswire.com/news-release/2025/07/28/3122523/29489/en/AIM-ImmunoTech-Reports-Positive-Mid-year-Safety-and-Efficacy-Data-from-Phase-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-T.html
Jul 28, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next